PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Venus Medtech Hangzhou Inc (2500.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCNE100003PJ8
SectorHealthcare
IndustryMedical Devices

Highlights

Market CapHK$2.48B
Revenue (TTM)HK$452.11M
Gross Profit (TTM)HK$324.34M
EBITDA (TTM)-HK$694.36M
Year RangeHK$3.74 - HK$12.78
Target PriceHK$9.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with 2500.HK

Venus Medtech Hangzhou Inc

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Venus Medtech Hangzhou Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%OctoberNovemberDecember2024FebruaryMarch
-86.95%
67.72%
2500.HK (Venus Medtech Hangzhou Inc)
Benchmark (^GSPC)

S&P 500

Returns By Period

Venus Medtech Hangzhou Inc had a return of 0.00% year-to-date (YTD) and -51.64% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date0.00%10.16%
1 month0.00%3.47%
6 months15.40%22.20%
1 year-51.64%30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20240.00%0.00%
2023-22.90%-16.82%-4.73%26.86%0.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Venus Medtech Hangzhou Inc (2500.HK) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
2500.HK
Venus Medtech Hangzhou Inc
-0.92
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Venus Medtech Hangzhou Inc Sharpe ratio is -0.92. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.92
2.77
2500.HK (Venus Medtech Hangzhou Inc)
Benchmark (^GSPC)

Dividends

Dividend History


Venus Medtech Hangzhou Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-94.09%
0
2500.HK (Venus Medtech Hangzhou Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Venus Medtech Hangzhou Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Venus Medtech Hangzhou Inc was 95.95%, occurring on Oct 26, 2023. The portfolio has not yet recovered.

The current Venus Medtech Hangzhou Inc drawdown is 94.09%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.95%Jan 26, 2021677Oct 26, 2023
-30.95%Oct 14, 202030Nov 25, 202041Jan 25, 202171
-26.84%Jul 9, 202038Aug 31, 202024Oct 6, 202062
-24.61%May 21, 20206May 28, 202014Jun 17, 202020
-17.96%Feb 28, 202010Mar 12, 202018Apr 7, 202028

Volatility

Volatility Chart

The current Venus Medtech Hangzhou Inc volatility is 0.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%OctoberNovemberDecember2024FebruaryMarch0
2.80%
2500.HK (Venus Medtech Hangzhou Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Venus Medtech Hangzhou Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items